Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Phenelzine

What is Phenelzine?

CAS No: 51-71-8

Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Phenelzine is a pharmaceutical substance or active ingredient. Its pharmacological properties and the available toxicological evidence may be relevant to evaluating potential occupational exposure and product carryover. A substance-specific assessment should distinguish established information from assumptions and document the basis for any recommended exposure controls.

A PDE or ADE sets a health-based limit on daily exposure to Phenelzine from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Where relevant information is available, the pharmacological activity of Phenelzine can help identify effects that may be important for a health-based exposure assessment. Evaluators consider the reliability and relevance of the evidence rather than assuming that therapeutic activity alone determines an exposure limit. The selected critical effect, dose-response basis, and uncertainty factors should be explained in the assessment.

If Phenelzine is a substance with relevant therapeutic-use information, dose information may contribute context to the assessment, but it does not by itself establish a PDE, ADE, or OEL. The evaluator must consider the quality and relevance of the full evidence package, including critical effects and route of exposure. Any use of dose information should be scientifically justified and clearly documented.

The assessment of Phenelzine may consider repeat-dose toxicity, genotoxicity, reproductive and developmental toxicity, carcinogenicity, and relevant pharmacological effects, depending on the available evidence and substance type. The critical effect is selected by evaluating study quality, relevance, and dose-response information. Any missing evidence or reliance on read-across should be explained transparently in the report.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Phenelzine in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

A PDE or ADE for Phenelzine applies within the route and purpose defined by the assessment; it should not automatically be treated as interchangeable across oral, inhalation, and dermal exposure. Route-to-route extrapolation requires scientific justification and may need additional evidence. The report should state its scope, assumptions, and intended use so the value is applied appropriately.

An occupational exposure limit report for Phenelzine provides a scientific benchmark for evaluating workplace exposure when supported by the available toxicological and occupational-health evidence. It can inform exposure monitoring, engineering controls, work practices, and appropriate personal protective equipment. The OEL should be used as part of a broader risk assessment, not as a substitute for controlling exposure at source.

A scientifically justified PDE for Phenelzine can be used as a health-based input when evaluating potential residue carryover from shared equipment into a subsequent product. Cleaning validation also requires consideration of the process, equipment, analytical method, and applicable acceptance criteria. The PDE does not by itself establish every cleaning limit; its use and any additional calculations should be documented.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Phenelzine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo